LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (LXRX)

Q: What does CUSIP 528872302 represent in this 13F holders report?

CUSIP 528872302 is the security identifier for LXRX - LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share used to aggregate holder disclosures.

Q: How many institutions held LXRX - LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share in Q2 2025?

121 institutional investors reported LXRX - LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share for Q2 2025. Use the holders table for investor-level position and value details.

CUSIP: 528872302

Q2 2025 13F Holders as of 30 Jun 2025

Type / Class: Equity / Common Stock, par value $0.001 per share
Shares outstanding: 427,442,892
Total 13F shares: 256,310,843
Share change: -9,388,843
Total reported value: $242,983,204
Put/Call ratio: 32%
Price per share: $0.95
Number of holders: 121
Value change: -$6,845,383
Number of buys: 59
Number of sells: 67

Quarterly Holders Quick Answers

What is CUSIP 528872302?
CUSIP 528872302 identifies LXRX - LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2025
Previous quarter: Q1 2025

Recent filing periods for CUSIP 528872302:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of LXRX - LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
International S.c.a. Artal	3/4/5	Director, 10%+ Owner	— class O/S missing	136,180,481	$356,792,860	—	10 May 2024	3/4/5
Siren, L.L.C.	3/4/5 13F	Director, 10%+ Owner · Individual	9.1% from 13F	35,402,689	$92,755,045	—	25 Jul 2024	3/4/5 13F
Artal Group S.A.	13F	Company	32%	136,180,481	$62,643,021	—	31 Mar 2025	13F
FMR LLC	13D/G 13F	Company	10%	38,137,535	$26,696,274	+$2,516,037	30 Jun 2025	13D/G 13F
Invus US Partners LLC	3/4/5	Director, 10%+ Owner	— class O/S missing	5,782,749	$6,090,969	—	05 Aug 2022	3/4/5
BlackRock, Inc.	13F	Company	2.3%	10,013,007	$4,613,995	—	31 Mar 2025	13F
VANGUARD GROUP INC	13F	Company	2.2%	9,557,175	$4,405,858	—	31 Mar 2025	13F
Schonfeld Strategic Advisors LLC	13F	Company	1.9%	8,212,993	$3,784,546	—	31 Mar 2025	13F
Lonnel Coats	3/4/5	Chief Executive Officer, Director	— mixed-class rows	2,109,255 mixed-class rows	$3,507,748	—	28 Feb 2024	3/4/5
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.86%	3,689,271	$1,700,415	—	31 Mar 2025	13F
STATE STREET CORP	13F	Company	0.61%	2,607,574	$1,201,570	—	31 Mar 2025	13F
CIBC Private Wealth Group LLC	13F	Company	0.52%	2,240,000	$1,122,464	—	31 Mar 2025	13F
Jeffrey L. Wade	3/4/5	President and COO	— mixed-class rows	729,441 mixed-class rows	$1,106,796	—	08 Jul 2024	3/4/5
UBS Group AG	13F	Company	0.49%	2,095,340	$965,951	—	31 Mar 2025	13F
Ikarian Capital, LLC	13F	Company	0.33%	1,417,952	$653,393	—	31 Mar 2025	13F
B. Kassler Taub	3/4/5	SVP, Regulatory & QA	— mixed-class rows	431,995 mixed-class rows	$597,845	—	28 Feb 2024	3/4/5
AQR CAPITAL MANAGEMENT LLC	13F	Company	0.27%	1,173,225	$540,622	—	31 Mar 2025	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.27%	1,150,771	$530,275	—	31 Mar 2025	13F
TANG CAPITAL MANAGEMENT LLC	13F	Company	0.27%	1,150,268	$530,043	—	31 Mar 2025	13F
NORTHERN TRUST CORP	13F	Company	0.26%	1,109,887	$511,435	—	31 Mar 2025	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.22%	951,135	$438,283	—	31 Mar 2025	13F
Hennion & Walsh Asset Management, Inc.	13F	Company	0.19%	830,054	$382,489	—	31 Mar 2025	13F
GSA CAPITAL PARTNERS LLP	13F	Company	0.19%	807,492	$372,000	—	31 Mar 2025	13F
Monaco Asset Management SAM	13F	Company	0.17%	734,148	$338,295	—	31 Mar 2025	13F
Ph.D. Alan J. Main	3/4/5	EVP, Innov & Chem Sciences	— mixed-class rows	1,228,681 mixed-class rows	$318,646	—	28 Feb 2025	3/4/5
Brian T. Corrigan	3/4/5	SVP, Regulatory & QA	— mixed-class rows	1,121,660 mixed-class rows	$300,602	—	13 Feb 2025	3/4/5
MORGAN STANLEY	13F	Company	0.15%	641,629	$295,662	—	31 Mar 2025	13F
ACADIAN ASSET MANAGEMENT LLC	13F	Company	0.13%	573,688	$263,000	—	31 Mar 2025	13F
BBR PARTNERS, LLC	13F	Company	0.13%	570,000	$262,656	—	31 Mar 2025	13F
Philippe Amouyal	3/4/5	Director	— mixed-class rows	478,292 mixed-class rows	$241,880	—	03 Jun 2025	3/4/5
Thomas Garner	3/4/5	SVP, Chief Commercial Officer	— mixed-class rows	454,260 mixed-class rows	$239,236	—	08 Feb 2024	3/4/5
Robert J. Lefkowitz MD	3/4/5	Director	— mixed-class rows	130,080 mixed-class rows	$223,156	—	13 May 2024	3/4/5
Nantahala Capital Management, LLC	13F	Company	0.11%	460,850	$212,360	—	31 Mar 2025	13F
BOOTHBAY FUND MANAGEMENT, LLC	13F	Company	0.11%	454,891	$209,614	—	31 Mar 2025	13F
Virtus Investment Advisers, LLC	13F	Company	0.1%	436,672	$201,218	—	31 Mar 2025	13F
Christopher J. Sobecki	3/4/5	Director	— mixed-class rows	396,983 mixed-class rows	$200,413	—	03 Jun 2025	3/4/5
GROUP ONE TRADING LLC	13F	Company	0.09%	365,806	$168,563	—	31 Mar 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.08%	355,152	$163,654	—	31 Mar 2025	13F
Sam L. Barker	3/4/5	Director	— mixed-class rows	317,577 mixed-class rows	$159,916	—	03 Jun 2025	3/4/5
Bank of New York Mellon Corp	13F	Company	0.07%	310,119	$142,902	—	31 Mar 2025	13F
Judith L. Swain	3/4/5	Director	— mixed-class rows	278,292 mixed-class rows	$139,880	—	03 Jun 2025	3/4/5
Invesco Ltd.	13F	Company	0.07%	285,759	$131,678	—	31 Mar 2025	13F
Diane E. Sullivan	3/4/5	Director	— mixed-class rows	229,928 mixed-class rows	$115,215	—	03 Jun 2025	3/4/5
ALLIANCEBERNSTEIN L.P.	13F	Company	0.06%	246,121	$113,413	—	31 Mar 2025	13F
Ph.D. Kiernan Seth	3/4/5	VP, Chief Commercial Officer	— mixed-class rows	379,163 mixed-class rows	$104,343	—	28 Feb 2023	3/4/5
Squarepoint Ops LLC	13F	Company	0.05%	195,409	$90,044	—	31 Mar 2025	13F
IEQ CAPITAL, LLC	13F	Company	0.04%	177,302	$81,701	—	31 Mar 2025	13F
SIMPLEX TRADING, LLC	13F	Company	0.04%	174,982	$80,000	—	31 Mar 2025	13F
Point72 Asia (Singapore) Pte. Ltd.	13F	Company	0.04%	171,147	$78,865	—	31 Mar 2025	13F
Cerity Partners LLC	13F	Company	0.04%	170,387	$78,514	—	31 Mar 2025	13F

Institutional Holders of LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (LXRX) as of Q2 2025

As of 30 Jun 2025, LEXICON PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (LXRX) was held by 121 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 256,310,843 shares. The largest 10 holders included Artal Group S.A., Siren, L.L.C., FMR LLC, VANGUARD GROUP INC, Schonfeld Strategic Advisors LLC, BlackRock, Inc., Sessa Capital IM, L.P., GSA CAPITAL PARTNERS LLP, CIBC Private Wealth Group LLC, and GEODE CAPITAL MANAGEMENT, LLC. This page lists 120 institutional shareholders reporting positions in this security for the Q2 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2025 vs Q1 2025 Across Filers

Q1 2025 holders

124

Q2 2025 holders

121

Holder diff

-3

Investor	Q1 2025 Shares	Q2 2025 Shares	Share Diff	Share Chg %	Q1 2025 Value $	Q2 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.